32 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease in HIV-AIDS ... Papillomavirus (HPV ... Hepatitis A virus (HAV ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease in HIV-AIDS ... Papillomavirus (HPV ... Hepatitis A virus (HAV ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
known to have HIV ... diagnosed with HIV ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
HIV/AIDS Medications - Targets of Action

Fusion inhibitors
Inhibitors of reverse transcriptase
Inhibitors of HIV protease

#HIVAIDS #pharmacology #targets #action
HIV/AIDS Medications ... Inhibitors of HIV ... protease #HIVAIDS ... #pharmacology #
HIV Antiretroviral Pharmacokinetic Boosters - Ritonavir & Cobicistat 

Ritonavir & Cobicistat are 2 pharmacokinetic boosters used
HIV Antiretroviral ... boosters used in HIV ... treatment to increase ... Ritonavir #Cobicistat #HIV ... #Boosters #Pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Infections in HIV-AIDS ... to 5 mg/kg/day IV ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Infections in HIV-AIDS ... PO (or 400 mg IV ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... amphotericin B 2–4 mg/kg IV ... Leishmaniasis #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... for effective treatment ... IDSA #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Trypanosomiasis) in HIV-AIDS ... duration same as for treatment ... Disease Note: Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology